Clinical pharmacology of ramipril.

[1]  S. Ljungman,et al.  Pharmacokinetics and pharmacodynamics of ramipril in renal failure. , 1987, The American journal of cardiology.

[2]  P. D. de Leeuw,et al.  Preliminary Experiences with HOE 498, a Novel Long-Acting Converting Enzyme Inhibitor, in Hypertensive Patients , 1985, Journal of cardiovascular pharmacology.

[3]  B. W. East,et al.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. , 1985, British heart journal.

[4]  S. Ball,et al.  A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man. , 1985, British journal of clinical pharmacology.

[5]  S. Ball,et al.  A need for new converting enzyme inhibitors? , 1985, British medical journal.

[6]  C. Zoccali,et al.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. , 1984, British journal of clinical pharmacology.

[7]  J. Reid,et al.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. , 1984, British medical journal.

[8]  J. Reid,et al.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. , 1982, British journal of clinical pharmacology.

[9]  N. Markandu,et al.  Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. , 1981, British medical journal.

[10]  N. Markandu,et al.  Maintenance of blood pressure by the renin–angiotensin system in normal man , 1981, Nature.

[11]  H. Eckert,et al.  Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. , 1984, Arzneimittel-Forschung.

[12]  H. Eckert,et al.  Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers. , 1984, Arzneimittel-Forschung.

[13]  P. Bünning.  Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat. , 1984, Arzneimittel-Forschung.

[14]  R. Geiger.  Chemistry of the inhibitors of the renin-angiotensin system. , 1984, Arzneimittel-Forschung.